VF5 Stock Chart & Stats
€0.11
>-€0.01(-2.21%)
At close: 4:00 PM EDT
€0.11
>-€0.01(-2.21%)
Day’s Range― - ―
52-Week Range€0.07 - €0.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€64.74M
Enterprise Value€77.17M
Total Cash (Recent Filing)€5.36M
Total Debt (Recent Filing)€278.87K
Price to Earnings (P/E)―
Beta0.13
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding561,218,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)21.53
Price to Sales (P/S)28.32
P/FCF Ratio-3.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€36.37K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe latest annual revenue increase indicates improving commercial traction and a growing base from which the company can develop its antimicrobial platform. If sustained, this expansion could provide greater operating scale and help support future investment in product development and commercialization.
Modest LeverageLow debt relative to equity provides some balance-sheet flexibility and limits the immediate burden of interest and debt service. This gives the company more room to direct capital toward its photodynamic antimicrobial programs, although continued losses could still change its funding needs.
Defined Healthcare ApplicationA focused application in antimicrobial treatment and healthcare-associated infection prevention gives the company a clearly defined medical need to address. Concentrating on photodynamic technology may support specialization and product development around clinical infection-control use cases over time.
Bears Say
Severe Profitability WeaknessExtremely negative profitability and the sharp gross-margin decline show that revenue growth has not yet translated into a sustainable earnings model. Persistently weak margins can constrain reinvestment capacity, increase dependence on financing, and make future scaling less economically certain.
Worsening Cash BurnIncreasing operating and free-cash-flow outflows raise the company’s ongoing funding requirement while its commercial model is still developing. Unless revenue scales materially or spending is reduced, continued burn could require additional capital and dilute financial flexibility over the next several quarters.
Equity Volatility And Funding RelianceMaterial changes in equity, including a prior period of negative equity, indicate that the capital structure can shift substantially as losses continue. This dependence on external funding may limit strategic flexibility and expose the company to financing pressure while profitability remains distant.
Ondine Biomedical, Inc. News
VF5 FAQ
What was Ondine Biomedical, Inc.’s price range in the past 12 months?
Ondine Biomedical, Inc. lowest stock price was €0.07 and its highest was €0.20 in the past 12 months.
What is Ondine Biomedical, Inc.’s market cap?
Ondine Biomedical, Inc.’s market cap is €64.74M.
When is Ondine Biomedical, Inc.’s upcoming earnings report date?
Ondine Biomedical, Inc.’s upcoming earnings report date is May 20, 2027 which is in 218 days.
How were Ondine Biomedical, Inc.’s earnings last quarter?
Ondine Biomedical, Inc. released its earnings results on Sep 30, 2026. The company reported -€0.019 earnings per share for the quarter.
Is Ondine Biomedical, Inc. overvalued?
According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Overvalued.
Does Ondine Biomedical, Inc. pay dividends?
Ondine Biomedical, Inc. does not currently pay dividends.
What is Ondine Biomedical, Inc.’s EPS estimate?
Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ondine Biomedical, Inc. have?
Ondine Biomedical, Inc. has 561,218,140 shares outstanding.
What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?
Ondine Biomedical, Inc. reported an EPS of -€0.019 in its last earnings report. Following the earnings report the stock price went up 4.651%.
Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?
Currently, no hedge funds are holding shares in DE:VF5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ondine Biomedical, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.09%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
0.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ondine Biomedical, Inc.
Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.
Technical Analysis
Avacta Group plc
―
SkinBioTherapeutics
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Oxford Nanopore Technologies PLC
―